Metabolic syndrome is a symptom complex that combines abdominal obesity, insulin resistance, hyperglycemia, dyslipidemia and arterial hypertension. One of the complications of metabolic syndrome is sexual dysfunction in men.
The objective: is to evaluate the efficacy and tolerability of udenafil 200 mg in the treatment of erectile dysfunction in patients with metabolic syndrome.
Materials and methods. The clinical efficacy of the IV generation PDE-5 inhibitor medicine udenafil in 76 patients with erectile dysfunction of mixed origin and with metabolic syndrome in dynamics was studied. The average age was 51,6±8,2 years. The observation period was 12 weeks, but the control of metabolic syndrome parameters (anthropometry, review, biochemical blood tests) and the assessment of erectile function were carried out for 6 months.
Results. After 12 weeks, patients achieved positive results in weight loss, BMI and waist circumference, although not significantly. It is necessary to note the positive changes in the indicators of the cardiovascular system. The downward trend was demonstrated by such indicators as heart. Diet therapy and taking statins have improved the indicators of fat metabolism. Correction of metabolic disorders in patients was accompanied by an increase in total and free testosterone. However, there was no statistically significant difference in the degree of increase in the concentration of androgens. Correction of metabolic disorders in patients was accompanied by an increase in total and free testosterone.
During treatment, almost all integrative indices of IIEF increased. Specifically, the index «erectile function» improved 2,26 times (p<0,01), «satisfaction with intercourse» 2,59 times (p<0,001), «orgasm» 2,0 times (p<0,01), «libido» – 2,9 times (p<0,001), «general satisfaction» 2,3 times (p<0,01). According to various indicators, the sexual function of men with metabolic syndrome and erectile dysfunction improved 2–2,9 times. Changes in cavernous blood flow on Doppler ultrasonography showed an increase in peak systolic blood flow rate by 1,5 times, which is associated with the udenafil half-life. Our data indicate that the use of the medicine udenafil is perspective in men with erectile dysfunction and metabolic syndrome and in those who do not have stable family-sexual relations to ensure spontaneity of sexual relations.
Conclusions. Udenafil can be considered as a first-line medecine in the treatment of erectile dysfunction in patients with metabolic syndrome.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
Mamedov M.N. Guidelines for the diagnosis and treatment of metabolic syndrome. M.: Multiprint, 2005. – 59–65 р.
Mamedov M.N., Oganov R.G. Epidemiological aspects of metabolic syndrome. Cardiology. 2004;9:4–6.
Mamedov M.N. Is it possible to diagnose and treat metabolic syndrome in real practice. Attending physician. 2006;6:34-9.
Khutiev T.V. Chernyshev A.V., Mashkina E.A. Metabolic syndrome. Information and methodological guide for doctors. Sochi. 2007. – 102 p.
Standi E. Aetiology and consequences of the metabolic syndrom. Europen Heart Journal. 2005;7(D):10-3.
Khutiev T.V. Chernyshev A.V., Bykov A.T. Diagnostics, prevention and treatment of metabolic syndrome. Teaching aid. Sochi. – 2015. – 192 p.
Chernyshev A.V. Diagnostics and rehabilitation treatment of metabolic syndrome and in sanatorium conditions. Questions of balneology, physiotherapy and exercise therapy. 2010;3:42-6.
Chernyshev A.V., Bykov A.T., Sorochinskaya I.N. The use of the Kardiomed training system in the complex sanatorium treatment of patients with metabolic syndrome. Doctor.Ru. 2013;10(88):9-13.
Chernyshev A.V. Bykov A.T., Sorochinskaya I.N. Treatment program for patients with metabolic syndrome in a sanatorium. Health resort medicine. 2013;3:41-5.
Chernyshev A.V. Sorochinskaya I.N. Optimization of sanatorium-resort treatment in patients with metabolic syndrome. Questions of balneology, physiotherapy and medical physical culture. 2012;89(6):12-6.
Chernyshev A.V. Tishakov A.Yu., Bitsadze A.N. Non-drug treatment of arterial hypertension in patients with metabolic syndrome in a resort. Military Medical Journal. 2009;3:80-1.
Karpov Yu.A., Sorokin E.V. On lipid-lowering therapy in metabolic syndrome. Heart. 2006;5(7):356-9.
Chernyshev A.V., Bykov A.T., Khutiev T.V. Optimization of rehabilitation treatment for patients with ischemic heart disease and metabolic syndrome. Bulletin of restorative medicine. 2010;1:54-8.
Chazova I.E. Mychka V.B., Kislyak O.A. Recommendations of the experts of the All-Russian Scientific Society of Cardiology for the diagnosis and treatment of metabolic syndrome. M., 2009. – 21 p.
Mkrtumyan A.M. Features of the course and treatment of carbohydrate metabolic disorders in metabolic syndrome. Heart. 2005;4(5):273-6.
Demir T. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int. J. Urol. 2006;13(4):385-8.
Esposito K., Giugliano F., Martedi E. et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabet. Care 2005;28(5):1201-3.
Gunduz M.I. et al. Relationship between metabolic syndrome and erectile dysfunction. Asian J. Androl. 2004;6(4):355-8.
Parazzini F., Menchini F.F., Bortolotti A. et al. Frequency and determinants of erectile dysfunction in Italy. Eur. Urol. 2000;37:43-9.
Mazo EB, Gamidov SI, Mamedov MN, Iremashvili VV Pathogenesis and diagnosis of erectile dysfunction in patients with metabolic syndrome. In the book: Materials of the III All-Russian scientific-practical. conf. Topical issues of diagnostics and treatment of metabolic syndrome. 2006. 71 р.
American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple’s problem-2003 update. AACE Male Sexual Dysfunction Task Force (Co-Chairman: Guay AT and Spark RF). Endocrine Pract. 2003;9(1):77-95.
Ametov AS, Teodorovich OV, Kondratyeva LV, Popova A. Yu. Some aspects of the pathogenesis and treatment of erectile dysfunction in obese patients. Ter. arch. 2006;78(2):92-4.
Anderson R.A., Bancroft W., Wu F.C.W. The effects of exogenous testosterone on sexuality and mood in normal men. Clin. Endocrinol. Metab. 1982;7S:1503-7.
Esposito K et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized trial. J.A. M.A. 2004;291:2978-84.
Rosen R. C., Fisher W. A., Eardley I. et al. Men’s Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) Study: I. Prevalence of erectile dysfunction and related health concerns in he general population. Curr. Med. Res. Opin. 2004;20(5):607-17.
Derby C. A., Barbour M. M., Hume A. L., McKinlay J. B. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001;21(6):676-83.
Bruckert E., Giral P., Heshmati H. M., Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J. Clin. Pharmacol. T her. 1996;21(2):89-94.
Alyaev Yu. G., Ronkin MA, Esilevsky Yu. M. et al. A systemic approach to studying the effect of Levitra in patients with chronic prostatitis and erectile dysfunction. Urology 2005;2:53-9.
O. F. Vozianov, I. І. Gorpinchenko «Dosvid stosuvannya viagri in Ukraine» Sexology and Andrology, Kiev, 2000, Issue 5, p. 3-5.
I.I. Gorpinchenko. Erectile dysfunction: diagnosis and modern methods of treatment. Men’s health. 2002;1:9-11.
Gorpinchenko II, Miroshnikov Ya. O. Erectile dysfunction. L., «Medicine to Light».
Buva J. Treatment with sildenafil, four years of experience. Men’s health. 2002;2:11-3.
Bell AS, Palmer MJ. Novel phosphodiesterase type 5 modulators: a patent survey (2008–2010). Expert Opin Ther Pat. 2011;21(10):1631-41.
Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902-12.
Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553–7.
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med. 2010;7(5):1928-36.
Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008;68(2):231-50.
Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res. 2002;25(6):873–8.
Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946–53.
Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sex Med. 2010;7(6):2209-16.
Moon DG, Yang DY, Lee CH, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011;8(7):2048-61.
Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res. 2009;21(2):122-8.
Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60(2):380–7.
Paick JS, Kim SW, Park YK, et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med. 2009;6(11):3166-76.
Ortac M, ayan S, Calis，kan MK, et al. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study. Andrology. 2013;1(4):549–55.
Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacoki-netics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848–54.
Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci. 2003;92(11):2185-95.
Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29(3):297-310.
Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C–12C.
Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1-52.
European Associacion of Urology. Pocet Guidelines. 2017 edition.
Mychka VB et al. Drug treatment of obesity in patients with metabolic syndrome. Cardiovasc. ter. and profilact. 2005;4:79-84.
Fogari R., Zoppi A., Poletti L. et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am. J. Hypertens. 2001;14(1):27-31.
Feldman II. A., Goldstein I, Hatzichristou D. G. et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J. Urol. (Baltimore) 1994;151:151-4.